Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine and Carfilzomib in Relapsed/Refractory Multiple Myeloma
NCT04163107Phase 1Completed
- Sponsor
- Norwegian University of Science and Technology
- Start
- Jan 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hydroxychloroquine in multiple myeloma (MM), sponsored by Norwegian University of Science and Technology. Primary endpoint: Maximum Tolerated Dose of Hydroxychloroquine at 3 months. Started Jan 2020; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04163107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04163107.